Dynavax's Z-1018 shingles vaccine matched Shingrix in immune response with fewer side effects, advancing to Phase 2 in older adults in 2025.

Dynavax’s lofty ambition to snatch Shingrix’s crown got off to a promising start after the biopharma’s investigational shingles vaccine held its own against GSK’s mainstay in the first part of a phase ...

GSK PLC closed 14.28% short of its 52-week high of £16.79, which the company reached on September 9th.

British drugmaker GSK said on Monday that the U.S. Food and Drug Administration has accepted its application for priority ...

Dynavax Technologies (NASDAQ:DVAX) added ~7% in the premarket on Thursday after the company said that its experimental ...

British drugmaker GSK said on Wednesday it is in talks with the Trump administration about ways to lower U.S. drug costs, ...

Dynavax Technologies said on Thursday its experimental shingles vaccine generated a similar immune response as GSK's blockbuster shot Shingrix, while showing a better safety profile, in an ...

GSK plc stock is downgraded due to litigation risks, weak sales, and market pressures, dividend yield remains a bright spot. Click for more on GSK stock.

Topline Pharmaceutical heavyweight GSK on Wednesday said it had settled four lawsuits in the U.S. that claimed its popular heartburn drug Zantac causes cancer, averting a trial due to start in ...

GSK does have some important weaknesses as an investment vehicle, however. Chief among them is the lack of a clear-cut all-star in areas like cancer, rare diseases, or metabolic disorders.

GSK shares rose around 3% during early trading in London. The boost comes after the company said it expects sales for 2023 to rise between 12% to 13%, up from earlier predictions topping out at 10%.

GSK’s commitment follows last year’s announcements from Pfizer Inc. on investing €1.2 billion in its Belgian branch in Puurs, and a €300 million plan from Takeda in Lessines.